NK
☆    

India,
2024-04-30 06:33
(775 d 12:57 ago)

Posting: # 23966
Views: 3,060
 

 Orlistat PD Endpoint BE study [Regulatives / Guidelines]

Post reply
Dear All,

As per the USFDA recommendation, if we conduct the Orlistat PD Endpoint BE study, we may have data (fecal fat) for Baseline, Test, Ref1 and Ref2

Can anyone explain how to analyze the pharmacodynamic study data step by step? how to establish dose response relationship?. Any example dataset are available?

Kindly suggest, which software (WinNonlin/SAS/etc…) is required to analyze these data.

Regards
NK
 
UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
131 visitors (0 registered, 131 guests [including 20 identified bots]).
Forum time: 19:31 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5